Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending | |||
Banzel | Rufinamide | Lennox-Gastaut syndrome | List with clinical criteria and/or conditions | Complete | ||
Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | ||
Baraclude | Entecavir | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Basaglar | Insulin glargine | Diabetes mellitus, type 1; diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
Bavencio | Avelumab | metastatic Merkel Cell Carcinoma (mMCC) | Reimburse with clinical criteria and/or conditions | Complete |